Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0033774 (pruritus)
 14,546 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

One hundred thirty-nine patients with alopecia areata were treated with diphenylcyclopropenone. Before treatment, 85 patients had subtotal or total hair loss (greater than 90% bald area) and in the remaining patients scalp involvement was between 40% and 90%. The following three factors were found to be of prognostic significance: type of alopecia areata as documented before treatment, duration of the disease before therapy, and presence of nail changes. Other factors such as age at onset, sex, presence of atopic features, the extent of variation in the range of diphenylcyclopropenone concentrations during treatment, and sleep disturbances caused by pruritus did not influence the prognosis significantly.
 ...
PMID:Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone. 200 67

The aim of this study was to approach on a psychical point of view 27 patients suffering from chronic idiopathic urticaria (14), pruritus sine materia (6), alopecia areata (3), pathomimia (4), in order to examine the possibility that psychic disorders could act as triggering or aggravating the dermatological affection. Psychical assessment was evaluated by colloquy and by the administration of some psychodiagnostic tests: EPI, MMPI, Zung. The role of psychogenic factors in skin diseases is emphasized and the results obtained from the use of antidepressant and minor tranquilizer drugs are discussed.
 ...
PMID:[Preliminary approach to the mental component in dermatologic patients]. 257 43

We performed clinical trials to evaluate the therapeutic effects of Foltene in patients of the several types of hair fallings. Thirty patients with male pattern baldness, alopecia areata and seborrheic alopecia were included in this study. Foltene was applied every other day for 40 days, and followed by maintenance therapy of twice application a week. The duration of whole therapy was 6 months. We conclude that Foltene is an effective and agent for male pattern baldness, alopecia areata and seborrheic alopecia from the following results. Ten patients with male pattern baldness was treated with Foltene for 6 months. Foltene had therapeutic effects of 50% in hair regrowth, 70% in decreased hair falls, 30% in decreased dandruff, 50% in decreased seborrhea. Thirteen patients with alopecia areata was treated with Foltene for 6 months. Foltene had therapeutic effects of 61.6% in hair regrowth, 53.9% in decreased in hair falls, 53.9% in decreased dandruff, 77.0% in decreased seborrhea. Seven patients with seborrheic alopecia was treatment with Foltene for 6 months. Foltene had therapeutic effects of 85.8% in hair regrowth, 57.2% in decreased hair falls, 42.9% in decreased dandruff, 85.8% in decreased seborrhea. The degree of therapeutic success was related to the duration of therapy. The side effects were as followed: itching sensation developed in 2 patients (6.7%); tingling sensation in 3 patients (10.0%); burning sensation in 1 patient (3.3%); erythema in 3 patients (10.0%).
 ...
PMID:A clinical study of topical mucopolysaccharides & polydeoxyribonucleoprotein (Foltene) therapy in alopecia. 297 41

Anthralin cream 0.5% to 1.0% was used to treat 68 patients with severe alopecia areata. Therapy was relatively well tolerated, although all patients experienced pruritus and local erythema and scaling. Cosmetic response was seen in 17 (25%) of the patients, and was maintained during therapy in 12 (71%) of the 17 cosmetic responders. For the patients treated with 0.5% anthralin, the mean time to response (44 of 66 patients) was 11 weeks; the mean time to cosmetic response (13 of 66 patients) was 23 weeks. Duration of the current episode of hair loss did not correlate with cosmetic response. Compared with other currently available topical treatments, anthralin appears to be a reasonable therapeutic option for severe alopecia areata.
 ...
PMID:Evaluation of anthralin in the treatment of alopecia areata. 331 18

Providing dermatologic care in a prison setting is a challenge to the practitioner's ingenuity and patience because of cumbersome methods of transporting prisoners, poor compliance with prescribed regimens, and follow-up care that is not only inadequate but almost nonexistent. Certain prevalent infections such as tinea pedis and condyloma acuminatum probably are specifically induced by the prison environment. Alopecia areata is unexpectedly common and apparently associated with stress. Pruritus, which is common, is related to both environment and stress. Dermatologic diseases seen commonly in blacks are more prevalent because of the population demographics, yet pseudofolliculitis barbae is unusual as a complaint. In this article we review our experiences in establishing a first in-prison dermatology clinic.
 ...
PMID:Dermatologic care behind bars. 265 11

The safety and efficacy of 3% topical minoxidil were evaluated in the treatment of extensive patchy alopecia areata, alopecia totalis, and alopecia universalis. Patients with extensive patchy alopecia areata had greater than 50% scalp hair loss. In this double-blind study, thirty subjects applied minoxidil or placebo to half of the afflicted scalp area twice daily, with overnight petrolatum occlusion, for 1 year. Both male and female subjects, ranging in age from 9 to 65 years, were enrolled, fifteen subjects to each treatment group. Minoxidil applications were generally well tolerated except for three instances of scalp itching and dermatitis, two of which necessitated discontinuing the medication. Hair growth was seen in seven of eleven evaluable subjects (63.6%) in the minoxidil group and in five of fourteen evaluable subjects (35.7%) in the placebo group. Excellent, cosmetically acceptable hair growth was seen in three of eleven minoxidil-treated subjects (27.3%) and in one of fourteen placebo-treated subjects (7.1%). Examination of vital signs and laboratory measurements revealed no evidence of systemic effects of minoxidil. Seven of the twelve subjects assayed in the minoxidil group had detectable minoxidil serum levels, ranging from 0.4 to 7.5 ng/ml.
 ...
PMID:Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. 354 9

The important psychological functions of the human skin - the skin functions as a border, contact and sense organ and as an organ of expression - as well as causalgenetic aspects of psychodermatology and the most important psychodermatological diseases are reported. Frequent psychosomatic dermatoses like chronic urticaria (bibliography), pruritus (case report, perioral dermatitis and alopecia areata (case reports) are described. In atopic dermatitis, psoriasis vulgaris and acne rosacea psychological factors are involved in addition to constitutional factors. Psychovegetative dermatoses can be due to situational problems (stress), but dermatologic symptoms may also have a mere appellant character (e.g. slight effluvium). Dermatologic symptoms may occur in connection with psychoses (e.g. parasitophobia). Psychic dermatologic symptoms may also arise secundary to severe chronic dermatoses. In psychoneurotic diseases such as dermatitis arterficialis skin is the target organ. Therapeutical aspects are considered.
 ...
PMID:[Psyche and skin (author's transl)]. 746 38

Alopecia areata and trichotillomania present the most frequent causes of circumscribed hair loss in children. The connection between trichotillomania and alopecia areata has confused former observers. It may result from scratching at the site of alopecia areata that is symptomatic with pruritus, initiating a habit-forming behavior, or patients with a mental predisposition may artificially prolong the disfigurement as the hair on the bald patches of alopecia areata regrows. We have seen the concomitant occurrence of trichotillomania and alopecia areata in a 13-year-old boy, and confirmed the diagnosis by results of histopathologic examination. With regard to pathogenesis and prognosis, the differentiation of trichotillomania in connection with alopecia areata from the more common patterns of temporary localized childhood trichotillomania and severe adult trichotillomania is suggested.
 ...
PMID:Trichotillomania in connection with alopecia areata. 882 53

Neuropeptides (NP) are a heterogeneous group of proteins functioning as neurotransmitters, neuromodulators and neurohormones. More than fifty of these molecules have been described, and some have been detected in human skin through immunochemistry and radioimmunoassay. In this article we attempt to study the role played by some of these substances such as substance P (SP), calcitonin gene related peptide (CGRP), neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), somatostatin (S), and neurotensin (N). Several NP induce inflammatory response with edema and erythema. They can also induce the release of histamine by mastocytes, regulate cutaneous blood flow, and participate in sweat regulation and nociception. They also exert their action over several cells that participate in immunity, acting as mitotic, and chemotactic factors, inhibiting or stimulating inflammatory mechanisms. Specific NP have their receptors on epidermal cells. We will also try to study certain diseases in which NP play an important role in inducing or alleviating lesions, such as psoriasis, atopic eczema, alopecia areata, vitiligo, nodular prurigo, aquagenic pruritus, hypertrophic scars and other entities.
 ...
PMID:[Role of neuropeptides in dermatology]. 927 66

One of the possible unwanted side effects following contact immunotherapy of alopecia areata is skin hypopigmentation, either in the form of a transient, post-inflammatory hypopigmentation or as the development of a persistent, depigmented patch. A case of leucoderma occurring on the forehead of a 16-year-old girl following application of squaric acid dibutylester to the scalp for the treatment of alopecia areata is described. Past medical and family history were negative for vitiligo and autoimmune disorders. The hypopigmented patch was distant from the scalp area where squaric acid dibutylester had been applied, and it was not preceded by any sign of eczema, erythema or itch in the same area. Moreover, it faded as soon as treatment was discontinued. A 4-year follow-up revealed no evidence of vitiligo. In conclusion, the possible occurrence of a transient leucoderma in untreated areas should be included among the side effects of contact immunotherapy of alopecia areata with squaric acid dibutylester.
 ...
PMID:Transient leucoderma appearing in an untreated area following contact immunotherapy for alopecia areata. 964 75


1 2 3 4 5 Next >>